At the heart of NUZYRA® SurePath™ lies a suite of services that can help address access and affordability barriers.
Scroll down to learn about the key role our Specialty Pharmacy Network plays in the process.
BENEFITS OF USING
- Pharmacists understand the needs of your acute patients
- Pharmacies have NUZYRA in stock
- They provide PA support, utilizing CoverMyMeds® electronic prior authorization tool
- Our partners can provide patient services like bridge, copay, and support for our patient assistance program
Our Bridge Program provides eligible patients up to a 2-day supply of NUZYRA tablets in the event there is a delay in coverage during the benefits investigation with the patient’s insurance.
The majority of patients will receive their medication within 24 hours of the prescription being sent to the pharmacy.1
HOW THE SPECIALTY PHARMACY NETWORK CAN ASSIST
- Initiate the PA if needed
- Complete the PA with all required information
- Prepare the PA for final submission
Reimbursement support services, including coverage inquiry and billing and coding support, may be available to eligible patients. Call NUZYRA Central® to be connected with a field reimbursement specialist and to check the status of a patient’s medication. 1-877-4NUZYRA (1-877-468-9972)
NUZYRA CENTRAL® CAN HELP WITH:
- Verification of benefits, typically in 24 hours
- for both oral (tablets) and IV formulations
- for both commercially covered and Medicare Advantage patients
- Insurance forms
- Coordination of prior authorizations
Extra assistance for eligible patients:
Patients may qualify for additional assistance with medication through NUZYRA Central®, the NUZYRA® SurePath™ access and affordability offering.
For patients under hospital discharge, care coordinators can get started with NUZYRA Central® quickly, with streamlined online enrollment. NUZYRA Central® processing can begin immediately upon form receipt— even before discharge.
You (or a patient) can connect live to NUZYRA Central® for help at
M-F, 8 AM – 8 PM ET
Once-daily* NUZYRA is available
in oral and IV formulations
Considering NUZYRA for your patients?REQUEST SAMPLES
*For treatment of CABP, the oral loading dose is 300 mg twice on Day 1.1
NUZYRA® (omadacycline) is a tetracycline-class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms:
Community-Acquired Bacterial Pneumonia (CABP) caused by the following:
Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by the following:
Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
IMPORTANT SAFETY INFORMATION
NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs, or to any of the excipients.
WARNINGS AND PRECAUTIONS
Mortality imbalance was observed in the CABP clinical trial with eight deaths (2%) occurring in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. The cause of the mortality imbalance has not been established. All deaths, in both treatment arms, occurred in patients > 65 years of age; most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality.
The use of NUZYRA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.
The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.
Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline-class antibacterial drugs. NUZYRA is structurally similar to other tetracycline-class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline-class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs.
Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.
NUZYRA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions, including photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests), have been reported for other tetracycline-class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected.
Prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
The most common adverse reactions (incidence ≥2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation.
Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA.
Absorption of tetracyclines, including NUZYRA is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations.
USE IN SPECIFIC POPULATIONS
Lactation: Breastfeeding is not recommended during treatment with NUZYRA.
Please see Full Prescribing Information for NUZYRA.
- Data on file. Paratek Pharmaceuticals, Inc.